These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 11785037)

  • 21. [Parkinson disease. Directed use of modern therapy].
    Möller JC; Wächter T; Oertel WH
    MMW Fortschr Med; 2001 May; 143 Suppl 2():45-50. PubMed ID: 11434257
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dopamine agonist-based strategies in the treatment of Parkinson's disease.
    Antonini A; Barone P
    Neurol Sci; 2008 Dec; 29 Suppl 5():S371-4. PubMed ID: 19381765
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Parkinson-Control study: a 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease.
    Castro-Caldas A; Delwaide P; Jost W; Merello M; Williams A; Lamberti P; Aguilar M; Del Signore S; Cesaro P;
    Mov Disord; 2006 Apr; 21(4):500-9. PubMed ID: 16267842
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Dopamine agonist therapy in early Parkinson's disease. A survey of a Cochrane review].
    Bode M
    Ugeskr Laeger; 2009 Oct; 171(41):2996-9. PubMed ID: 19814927
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ropinirole therapy for Parkinson's disease.
    Pahwa R; Lyons KE; Hauser RA
    Expert Rev Neurother; 2004 Jul; 4(4):581-8. PubMed ID: 15853577
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Current preclinical findings on substances against Parkinson's disease].
    Gerlach M; Riederer P
    Nervenarzt; 2003 Mar; 74 Suppl 1():S2-6. PubMed ID: 12624677
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The effectiveness and tolerance of piribedil as adjunct therapy to levodopa in patients with Parkinson's disease: a nine month follow up].
    Salazar Tortolero G; Wix Ramos R; Salazar Aladrén P; Jiménez León JC
    Rev Neurol; 2004 Apr 16-30; 38(8):715-9. PubMed ID: 15122540
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatments for Parkinson disease--past achievements and current clinical needs.
    Poewe W
    Neurology; 2009 Feb; 72(7 Suppl):S65-73. PubMed ID: 19221317
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High-dose treatment with pergolide in Parkinson's disease patients with motor fluctuations and dyskinesias.
    Storch A; Trenkwalder C; Oehlwein C; Winkelmann J; Polzer U; Hundemer HP; Schwarz J
    Parkinsonism Relat Disord; 2005 Sep; 11(6):393-8. PubMed ID: 15993640
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Ropinirole in the treatment of Parkinson's disease: an update].
    Vivancos-Matellano F
    Rev Neurol; 2006 May 1-15; 42(9):542-8. PubMed ID: 16676278
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of apomorphine in Parkinson's disease.
    Stocchi F
    Neurol Sci; 2008 Dec; 29 Suppl 5():S383-6. PubMed ID: 19381769
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The 'magic' of L-dopa: why is it the gold standard Parkinson's disease therapy?
    Mercuri NB; Bernardi G
    Trends Pharmacol Sci; 2005 Jul; 26(7):341-4. PubMed ID: 15936832
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Medicinal treatment of idiopathic Parkinson's disease].
    Klockgether T
    Nervenarzt; 2003 Mar; 74 Suppl 1():S12-21. PubMed ID: 12624679
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Parkinson disease--new aspects of therapy].
    Schneider E
    Wien Med Wochenschr; 1988 Feb; 138(3):54-7. PubMed ID: 3285599
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Drug selection and timing of initiation of treatment in early Parkinson's disease.
    Schapira AH; Olanow CW
    Ann Neurol; 2008 Dec; 64 Suppl 2():S47-55. PubMed ID: 19127579
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pramipexole in Parkinson's disease. A short-term study using the combined levodopa-dopamine agonist test.
    Fabbrini G; Barbanti P; Aurilia C; Pauletti C; Meco G
    Funct Neurol; 2002; 17(4):199-201. PubMed ID: 12675263
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ropinirole as an adjunct to levodopa in the treatment of Parkinson's disease: a 16-week bromocriptine controlled study.
    Im JH; Ha JH; Cho IS; Lee MC
    J Neurol; 2003 Jan; 250(1):90-6. PubMed ID: 12527999
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of Parkinson's disease: levodopa as the first choice.
    Katzenschlager R; Lees AJ
    J Neurol; 2002 Sep; 249 Suppl 2():II19-24. PubMed ID: 12375059
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of a selective partial D1 agonist, CY 208-243, in de novo patients with Parkinson disease.
    Emre M; Rinne UK; Rascol A; Lees A; Agid Y; Lataste X
    Mov Disord; 1992; 7(3):239-43. PubMed ID: 1535688
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Parkinson disease].
    Moore AP; Clarke CE
    Praxis (Bern 1994); 2001 Jun; 90(23):1041-6. PubMed ID: 11447724
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.